Drug resistance is a major obstacle of most of anticancer therapeutics. Several clinical studies have described reduced response to antiangiogenic therapy targeting VEGF pathway over time followed by regrowth of treated tumors. As tumor angiogenesis is governed by multiple pathways, one difficulty in antiangiogenic therapy is the selective up-regulation of other pro-angiogenic factors, including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF), which bypasses VEGF and renders tumors refractory to anti-VEGF therapy. Although targeting VEGF pathway carries an enormous therapeutic potential, it is very likely that resistance to inhibition of these pathways will emerge as a potential obstacle to be overcome in clinical practice. The main goal of this study is to elucidate potential cellular and molecular mechanisms mediating tumor resistance to anti-VEGF therapy. The main hypothesis is that induction of other proangiogenic signaling, independent of VEGF, is the leading mechanism of development of tumor resistance and is associated with hypoxia in tumor microenvironment. Application of the innovative approaches to study this significant relationship could greatly expand our limited understanding of bypass mechanisms of tumors to anti-VEGF agents and provide rationale to select multi-targeting agents that counteract such mechanisms of resistance mediated by alternative proangiogenic signaling. This goal will be accomplished through the following Specific Aims: 1) Identify the pathways involved in crosstalk between VEGF and VEGF-independent proangiogenic signaling transduction in stroma-tumor co-cultures;2) Evaluate the roles of stromal cells rescuing tumors from the anti-VEGF therapy-induced hypoxia;and 3) Identify in vivo resistance signatures to anti-VEGF treatments using xenograft model. From these experiments, we will identify potential pathways of resistance to be targeted, and to validate in vitro and in vivo pre-clinical models for identifying resistance to targeted agents, thereby proving insight into the design of future therapeutic strategies for tumors refractory to anti-VEGF therapy.

Public Health Relevance

Prostate cancer remains as a major public health issue, with limited treatment options for the advanced disease setting. Angiogenesis inhibition is a newly emerging modality for prosate cancer. Identifying molecular mechanisms by which tumor microenvironment plays a role in mediating angiogenesis-resistance, which this application strives for, will benefit to exploit the full therapeutic potential ofthe angiangiogenic therapy for the prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-03
Application #
8723256
Study Section
Special Emphasis Panel (ZRR1)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Ramraj, Satish Kumar; Aravindan, Sheeja; Somasundaram, Dinesh Babu et al. (2016) Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget 7:18605-19
Zhang, Zhi; Subramaniam, Sabareesh; Kale, Justin et al. (2016) BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J 35:208-36
Huang, Qingling; Schneeberger, Valentina E; Luetteke, Noreen et al. (2016) Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther 15:2521-2529
Nguyen, Charles B; Kotturi, Hari; Waris, Gulam et al. (2016) (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res 76:4887-96
Corbin, Joshua M; Overcash, Ryan F; Wren, Jonathan D et al. (2016) Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer. Prostate 76:97-113
Srivastava, Akhil; Amreddy, Narsireddy; Babu, Anish et al. (2016) Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep 6:38541
Muralidharan, Ranganayaki; Babu, Anish; Amreddy, Narsireddy et al. (2016) Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology 14:47
Ha, Ji Hee; Ward, Jeremy D; Radhakrishnan, Rangasudhagar et al. (2016) Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus. Oncotarget 7:37664-37679
Kim, Tae-Dong; Jin, Fang; Shin, Sook et al. (2016) Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest 126:706-20
Amreddy, Narsireddy; Muralidharan, Ranganayaki; Babu, Anish et al. (2015) Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine 10:6773-88

Showing the most recent 10 out of 38 publications